# Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

> **NCT00270127** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 375 (actual)

## Conditions studied

- Anemia
- Cancer
- Neoplasm

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00270127
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-08
- **Primary completion:** —
- **Final completion:** 1998-09
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270127, "Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00270127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*